STOCK TITAN
  1. Home
  2. News
  3. ADVM

Adverum Biotechnologies, Inc. - $ADVM STOCK NEWS

Welcome to our dedicated page for Adverum Biotechnologies news (Ticker: $ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotechnologies stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adverum Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adverum Biotechnologies's position in the market.

News
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
Rhea-AI Summary
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced participation in the Evercore ISI 6th Annual HealthCONx Conference by its CFO and CDO. The webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences
-
News
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Rhea-AI Summary
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported positive preliminary aflibercept protein levels from the Phase 2 LUNA trial, indicating therapeutic activity. Long-term OPTIC data showed sustained benefits for patients. Initial LUNA safety and efficacy data expected in Q4 2023. Cash runway projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
earnings
-
News
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
Rhea-AI Summary
Adverum Biotechnologies, Inc. appoints Dr. C. David Nicholson as an independent member of its Board of Directors. Dr. Nicholson brings over forty years of pharmaceutical experience and deep experience in ophthalmology. His appointment reflects the company's commitment to excellence in clinical and preclinical development. Adverum's lead product candidate, Ixo-vec, is currently being evaluated in the Phase 2 LUNA trial for wet age-related macular degeneration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
management
News
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
Rhea-AI Summary
Adverum Biotechnologies announces updated data from the OPTIC extension study of patients with wet AMD, showing long-term benefit from Ixo-vec gene therapy. Key findings include an 84% reduction in annualized anti-VEGF injections and durable aflibercept protein levels up to 4.5 years post-treatment. The treatment continues to be well-tolerated. A summary of previously announced aflibercept protein levels from the LUNA study was also presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
Rhea-AI Summary
Adverum Biotechnologies announces positive initial data from Phase 2 LUNA trial for wet AMD treatment. Aflibercept protein levels at both 2E11 and 6E10 doses are within therapeutically active range. Gene therapy has potential to reduce treatment burden. Preliminary clinical activity and safety data are encouraging. Q4 2023: OPTIC trial long-term follow-up data to be presented. Q4 2023: Anticipated release of LUNA preliminary efficacy and safety data. Mid-2024: Additional LUNA data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
clinical trial
-
News
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Adverum Biotechnologies to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.39%
Tags
conferences
News
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Adverum Biotechnologies CFO to present at H.C. Wainwright conference on Sep 12, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences
-
News
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
Rhea-AI Summary
Dr. Ramelmeier joins Adverum as CTO to lead technology and operations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
management
-
News
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Rhea-AI Summary
Adverum Biotechnologies, a clinical-stage company focused on gene therapy for ocular diseases, announced that its CEO will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on August 16, 2023. The presentation will be available on-demand on the company's website, with a replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
conferences
News
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Adverum Biotechnologies provided an update on its Phase 2 LUNA trial for wet age-related macular degeneration (wet AMD). Enrollment in the trial has been completed, and data on aflibercept protein levels is expected in Q3 2023, with preliminary efficacy and safety data anticipated in Q4 2023. The company also announced that the combined OPTIC and LUNA trials will include approximately 90 subjects and will inform global pivotal trials. Adverum's cash runway is projected into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
earnings clinical trial
Stock ADVM logo
Adverum Biotechnologies, Inc.

Nasdaq:ADVM

ADVM Rankings

#3716 Ranked by Market Cap
#1276 Ranked by Stock Gains
N/A Ranked by Dividends

ADVM Stock Data

216.47M
11.72M
0.91%
80.01%
4.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About ADVM

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.